Asia Pacific active pharmaceutical ingredients market will grow by 8.8% annually with a total addressable market cap of $691.3 billion over 2021-2028, driven by rising adoption of biologics in disease management, increasing regulatory approvals, patent expiration of major drugs, growing trend of outsourcing and increase in geriatric population.
Highlighted with 92 tables and 68 figures, this 192-page report “Asia Pacific Active Pharmaceutical Ingredients (API) Market 2021-2028 by Synthesis (Synthetic, Biotech, HPAPI), Manufacturing Process (Captive, Merchant), Therapeutic Application, Drug Type, and Country: Trend Forecast and Growth Opportunity” is based on comprehensive research of the entire Asia Pacific active pharmaceutical ingredients market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2028 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific active pharmaceutical ingredients market in every aspect of the classification from perspectives of Synthesis, Manufacturing Process, Therapeutic Application, Drug Type, and Country.
Based on Synthesis, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2018-2028 included in each section.
Synthetic API
• Branded Synthetic API
• Generic Synthetic API
Biotech API by Drug Type:
• Monoclonal Antibodies
• Recombinant Proteins
• Vaccines
• Other Biotech APIs
Biotech API by Customer Base:
• Innovative Biologic API
• Generic Biosimilar API
Biotech API by Expression Technology:
• Mammalian Expression
• Microbial Expression
• Yeast Expression
• Insect Expression
• Other Expression Technologies
HPAPI
• Branded HPAPI
• Generic HPAPI
Based on Manufacturing Process, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2018-2028 included in each section.
Captive Manufacturing
• Branded Captive API
• Generic Captive API
Merchant Manufacturing by Drug Type:
• Branded Merchant API
• Generic Merchant API
Merchant Manufacturing by Drug Synthesis:
• Merchant Synthetic API
• Merchant Biotech API
By Therapeutic Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2018-2028 included in each section.
• Infectious Diseases
• Oncology
• Ophthalmology
• Cardiovascular Disorders
• Central Nervous System
• Pulmonary Disorders
• Orthopedics
• Other Applications
By Drug Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2018-2028 included in each section.
• Branded Prescription Drugs
• Generic Prescription Drugs
• OTC Drugs
Geographically, the following national/local markets are fully investigated:UK
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and data for annual revenue ($ bn) are available for 2018-2028. The breakdown of key national markets by Synthesis, Manufacturing Process, and Therapeutic Application, over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
AbbVie Inc.
Astrazeneca
Aurobindo Pharma Ltd.
BASF
Bayer AG
Boehringer Ingelheim
Catalent Inc.
Dr. Reddy's Laboratories
F. Hoffmann-La Roche
GlaxoSmithKline plc
Lonza Group
Lupin Limited
Merck & Co., Inc.
Mylan NV
Novartis International AG
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Thermo Fisher Scientific
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 9
1.1 Industry Definition and Research Scope 9
1.1.1 Industry Definition 9
1.1.2 Research Scope 10
1.2 Research Methodology 13
1.2.1 Overview of Market Research Methodology 13
1.2.2 Market Assumption 14
1.2.3 Secondary Data 14
1.2.4 Primary Data 14
1.2.5 Data Filtration and Model Design 15
1.2.6 Market Size/Share Estimation 16
1.2.7 Research Limitations 17
1.3 Executive Summary 18
2 Market Overview and Dynamics 21
2.1 Market Size and Forecast 21
2.1.1 Impact of COVID-19 on World Economy 22
2.1.2 Impact of COVID-19 on the Market 24
2.2 Major Growth Drivers 31
2.3 Market Restraints and Challenges 39
2.4 Emerging Opportunities and Market Trends 42
2.5 Porter’s Fiver Forces Analysis 46
3 Segmentation of Asia Pacific Market by Synthesis 50
3.1 Market Overview by Synthesis 50
3.2 Synthetic API 52
3.2.1 Branded Synthetic API 53
3.2.2 Generic Synthetic API 54
3.3 Biotech API 55
3.3.1 Biotech API by Drug Type 56
3.3.1.1 Monoclonal Antibodies 57
3.3.1.2 Recombinant Proteins 58
3.3.1.3 Vaccines 59
3.3.1.4 Other Biotech APIs 60
3.3.2 Biotech API by Category 61
3.3.2.1 Innovative Biologic API 62
3.3.2.2 Generic Biosimilar API 63
3.3.3 Biotech API by Expression Technology 64
3.3.3.1 Mammalian Expression 65
3.3.3.2 Microbial Expression 66
3.3.3.3 Yeast Expression 67
3.3.3.4 Insect Expression 68
3.3.3.5 Other Expression Technologies 69
3.4 HPAPI 70
3.4.1 Branded HPAPI 71
3.4.2 Generic HPAPI 72
4 Segmentation of Asia Pacific Market by Manufacturing Process 73
4.1 Market Overview by Manufacturing Process 73
4.2 Captive Manufacturing 75
4.2.1 Branded Captive API 76
4.2.2 Generic Captive API 77
4.3 Merchant Manufacturing 78
4.3.1 Merchant Manufacturing by Drug Type 79
4.3.1.1 Branded Merchant API 80
4.3.1.2 Generic Merchant API 81
4.3.2 Merchant Manufacturing by Drug Synthesis 82
4.3.2.1 Merchant Synthetic API 83
4.3.2.2 Merchant Biotech API 84
5 Segmentation of Asia Pacific Market by Therapeutic Application 85
5.1 Market Overview by Therapeutic Application 85
5.2 Infectious Diseases 87
5.3 Oncology 88
5.4 Ophthalmology 89
5.5 Cardiovascular Disorders 90
5.6 Central Nervous System 91
5.7 Pulmonary Disorders 92
5.8 Orthopedics 93
5.9 Other Applications 94
6 Segmentation of Asia Pacific Market by Drug Type 95
6.1 Market Overview by Drug Type 95
6.2 Branded Prescription Drugs 97
6.3 Generic Prescription Drugs 98
6.4 OTC Drugs 99
7 Asia-Pacific Market 2021-2028 by Country 100
7.1 Overview of Asia-Pacific Market 100
7.2 China 103
7.3 Japan 105
7.4 India 108
7.5 Australia 110
7.6 South Korea 112
7.7 Rest of APAC Region 114
8 Competitive Landscape 116
8.1 Overview of Key Vendors 116
8.2 New Product Launch, Partnership, Investment, and M&A 119
8.3 Company Profiles 120
AbbVie Inc. 120
Astrazeneca 122
Aurobindo Pharma Ltd. 127
BASF 130
Bayer AG 133
Boehringer Ingelheim 137
Catalent Inc. 142
Dr. Reddy's Laboratories 145
F. Hoffmann-La Roche 147
GlaxoSmithKline plc 149
Lonza Group 154
Lupin Limited 159
Merck & Co., Inc. 162
Mylan NV 165
Novartis International AG 168
Pfizer Inc. 171
Sanofi 176
Sun Pharmaceutical Industries Ltd. 179
Teva Pharmaceutical Industries Ltd. 182
Thermo Fisher Scientific 184
9 Investing in Asia Pacific Market: Risk Assessment and Management 186
9.1 Risk Evaluation of Asia Pacific Market 186
9.2 Critical Success Factors (CSFs) 189
Related Reports and Products 192
Selected Key Players:
AbbVie Inc.
Astrazeneca
Aurobindo Pharma Ltd.
BASF
Bayer AG
Boehringer Ingelheim
Catalent Inc.
Dr. Reddy's Laboratories
F. Hoffmann-La Roche
GlaxoSmithKline plc
Lonza Group
Lupin Limited
Merck & Co., Inc.
Mylan NV
Novartis International AG
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
Thermo Fisher Scientific
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Ěý
Ěý
*If Applicable.
